Zerlasiran siRNA Drug Lowers Lp(a) by 90% in Phase 2 Results Zerlasiran siRNA Drug Lowers Lp(a) by 90% in Phase 2 Results

Silence Therapeutics has announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Source Type: news
More News: Cardiology | Heart | Study